This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

As a medical editor who works in the area of blood lipids and coronary heart disease risk, I was called on to review literature on rhabdomyolysis related to the use of cerivastatin. As you know, cerivastatin was voluntarily withdrawn from the market by Bayer Pharmaceutical Division, West Haven, Conn, in August 2001 because of reports of sometimes fatal rhabdomyolysis.¹ In a case report published in the ARCHIVES in March of this year, Garcia-Valdecasas-Campelo et al² write that "no [previous] cases of rhabdomyolysis associated with cerivastatin therapy have been described." Yet even my quick PubMed search showed at least 5 reports published in 1999 or 2000 of rhabdomyolysis in cerivastatin users.^3-7 In 4 of 5 cases, cerivastatin was given in conjunction with gemfibrozil^3-4,6-7; in the fifth, concomitant therapy included immunosuppressant drugs for renal transplantation.⁵ It strikes me that there was a serious breakdown in the peer review process of the . . . [Full Text of this Article]

RELATED ARTICLE

Acute Rhabdomyolysis Associated With Cerivastatin Therapy
E. Garcia-Valdecasas-Campelo, E. Gonzalez-Reimers, A. Lopez-Lirola, E. Rodriguez-Rodriguez, and F. Santolaria-Fernandez
Arch Intern Med. 2001;161(6):893.
EXTRACT | FULL TEXT